Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. (Q40661166)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Morten Mau-Sorensen

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

3

Karin Leunen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Ruth Plummer

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Helen Swaisland

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Carla M L van Herpen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Guy Jerusalem

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Martijn P Lolkema

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Patricia Soetekouw

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Dorte Nielsen

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

James Spicer

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Anitra Fielding

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Karen So

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Wendy Bannister

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

L Rhoda Molife

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

5 August 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

Cancer Chemotherapy and Pharmacology

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

76

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

723-729

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26242220%20AND%20SRC:MED&resulttype=core&format=json

Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin.

20 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2836-2

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2836-2

Olaparib, PARP1 inhibitor in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2836-2

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2836-2

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2836-2

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2836-2

Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2836-2

Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2836-2

Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2836-2

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2836-2

Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-015-2836-2